Joshua M Tate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joshua M Tate has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Janelle B Gyorffy
Department of Internal Medicine, San Antonio Military Medical Center, San Antonio, TX, USA
1 shared publicationJeffrey A Colburn
Endocrinology Service, Department of Medicine, San Antonio Military Medical Center, San Antonio, TX, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2017
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 5
The importance of pheochromocytoma case detection in patients with neurofibromatosis type 1: A case report and review of literature
Neurofibromatosis type 1 is a complex, multi-system genetic disorder that is associated with an increased prevalence of pheochromocytoma and paraganglioma compared to the general population, 1.0%–5.7% versus 0.2%–0.6%, respectively. A delay in pheochromocytoma and paraganglioma diagnosis or undiagnosed pheochromocytoma and paraganglioma, as seen in normotensive and asymptomatic patients, may portend a significant morbidity and mortality risk due to excess catecholamine secretion. Currently, there are no generally accepted guidelines of screening for pheochromocytoma and paragangliomas in asymptomatic individuals of this population with approaches and practices varying considerably between physicians. Emerging data suggest benefit in routine pheochromocytoma and paraganglioma screening of all individuals with neurofibromatosis type 1. Herein, we present a case to highlight how routine case detection screening would have identified pheochromocytoma earlier in an active duty military member.
- 1 January 2017
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 5
Open AccessThe importance of pheochromocytoma case detection in patients with neurofibromatosis type 1: A case report and review of literature
Neurofibromatosis type 1 is a complex, multi-system genetic disorder that is associated with an increased prevalence of pheochromocytoma and paraganglioma compared to the general population, 1.0%–5.7% versus 0.2%–0.6%, respectively. A delay in pheochromocytoma and paraganglioma diagnosis or undiagnosed pheochromocytoma and paraganglioma, as seen in normotensive and asymptomatic patients, may portend a significant morbidity and mortality risk due to excess catecholamine secretion. Currently, there are no generally accepted guidelines of screening for pheochromocytoma and paragangliomas in asymptomatic individuals of this population with approaches and practices varying considerably between physicians. Emerging data suggest benefit in routine pheochromocytoma and paraganglioma screening of all individuals with neurofibromatosis type 1. Herein, we present a case to highlight how routine case detection screening would have identified pheochromocytoma earlier in an active duty military member.